ROS1 and non-small cell lung carcinoma: Studies have demonstrated a modest ORR of 13%-17% with single-agent ICI.91–93 Furthermore, prior exposure to an ICI can augment toxicities with subsequent targeted therapies across NSCLC, and the safety impact of sequential ICI and next-generation ROS1 TKI remains to be characterized fully.94,95 Thus, single-agent immunotherapy is not a favored treatment strategy and should only rarely be considered when other treatment options have been exhausted, with vigilant monitoring for toxicities if patients are subsequently reintroduced to a ROS1 TKI.